# A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies

> **NCT03538028** · PHASE1 · COMPLETED · sponsor: **Incyte Biosciences International Sàrl** · enrollment: 22 (actual)

## Conditions studied

- Cervical Cancer
- Microsatellite Instability (MSI)-High Endometrial Cancer
- Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ])
- Esophageal Cancer
- Hepatocellular Carcinoma
- Melanoma (Uveal Melanoma Excluded)
- Merkel Cell Carcinoma
- Mesothelioma
- MSI-high Colorectal Cancer
- Non-small Cell Lung Cancer (NSCLC)
- Ovarian Cancer
- Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Small Cell Lung Cancer (SCLC)
- Renal Cell Carcinoma (RCC)
- Triple-negative Breast Cancer
- Urothelial Carcinoma
- Diffuse Large B-cell Lymphoma

## Interventions

- **BIOLOGICAL:** INCAGN02385

## Key facts

- **NCT ID:** NCT03538028
- **Lead sponsor:** Incyte Biosciences International Sàrl
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-18
- **Primary completion:** 2020-10-07
- **Final completion:** 2020-10-07
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2020-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03538028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03538028, "A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03538028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*